Capital Viii, Llc Vivo Capi... Net Worth

The estimated Net Worth of Capital Viii, Llc Vivo Capi... is at least $48.2 Thousand dollars as of 25 January 2018. Capital Capi owns over 294,118 units of Menlo Therapeutics stock worth over $48,176 and over the last 7 years Capital sold MNLO stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Capi MNLO stock SEC Form 4 insiders trading

Capital has made over 1 trades of the Menlo Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 294,118 units of MNLO stock worth $5,000,006 on 25 January 2018.

The largest trade Capital's ever made was buying 294,118 units of Menlo Therapeutics stock on 25 January 2018 worth over $5,000,006. On average, Capital trades about 294,118 units every 0 days since 2018. As of 25 January 2018 Capital still owns at least 35,686 units of Menlo Therapeutics stock.

You can see the complete history of Capital Capi stock trades at the bottom of the page.

What's Capital Capi's mailing address?

Capital's mailing address filed with the SEC is 505 Hamilton Ave #200, Palo Alto, CA 94301, USA.

Insiders trading at Menlo Therapeutics

Over the last 7 years, insiders at Menlo Therapeutics have traded over $3,825,000 worth of Menlo Therapeutics stock and bought 3,655,938 units worth $21,205,011 . The most active insiders traders include Advisors Llcperceptive Life..., Llc Fmr, and Albert Cha. On average, Menlo Therapeutics executives and independent directors trade stock every 85 days with the average trade being worth of $572,944. The most recent stock trade was executed by Sharon Barbari on 20 August 2020, trading 75,000 units of MNLO stock currently worth $111,000.

What does Menlo Therapeutics do?

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Complete history of Capital Capi stock trades at Menlo Therapeutics

Menlo Therapeutics executives and stock owners

Menlo Therapeutics executives and other stock owners filed with the SEC include:

• Elisabeth Sandoval,
  Independent Director
• Patrick LePore,
  Independent Director
• Anthony Bruno,
  Director
• Rex Bright,
  Director
• Sharon Barbari,
  Director
• Matthew Wiley,
  Chief Commercial Officer
• Mutya Harsch,
  Chief Legal Officer, General Counsel
• Ronald Krasnow,
  Chief Compliance Officer
• Iain Stuart,
  Chief Scientific Officer
• Andrew Saik,
  Chief Financial Officer, Treasurer
• David Domzalski,
  Chief Executive Officer, Director
• Steven L Basta,
  Director
• Advisors Llcperceptive Life...,
  
• Ilan Hadar,
  CFO and Country Manager
• Stanley Hirsch,
  Director
• Partners 2007 Gp, L.P.Presi...,
  
• Global Strategic Fund Ii L....,
  10% owner
• Ventures Llc Remeditex,
  10% owner
• Capital Viii, Llc Vivo Capi...,
  
• Albert Cha,
  Director
• Llc Fmr,
  
• Scott M Whitcup,
  Director
• Mary Spellman,
  Chief Medical Officer
• Kristine M Ball,
  See Remarks
• David W J Mcgirr,
  Director
• Paul L Berns,
  Director
• Ted Ebel,
  Director
• Aaron Royston,
  Director
• Paul Kwon,
  Chief Scientific Officer